Good Manufacturing Practice for Medicinal Products in Bulgaria: an Analysis of Regulatory Inspection Findings

Abstract

Background: The manufacture of medicinal products for human use in the European Economic Area is governed by European Directives and Regulations stipulating the relevant principles and guidelines of Good Manufacturing Practice, describing the minimum standard to be fulfilled in the production processes.   Aim: To present analysis of the deficiencies reported following Good Manufacturing Practice inspections in Bulgaria in two consecutive years (2016, 2017) and to compare them with results from similar inspections reported by other EU member states.   Materials and methods: A retrospective study was carried out by reviewing the complete Good Manufacturing Practice inspection reports of all manufacturers conducted by the Bulgarian Drug Agency in 2016 and 2017, according to relevant requirements and applicable local legislation. The items reviewed were scope of inspection, type of companies, classification of deficiencies – ‘critical’, ‘major’ and ‘other significant deficiencies’, their nature and reference to EU Good Manufacturing Practice.   Results: The analyzed data included 55 inspections, revealing 460 various deficiencies, of which 2 were critical and 102 – major. Twenty inspections were performed in 2016 vs. 35 inspections in 2017. The pattern of deficiencies was similar to the findings of other EU regulatory agencies, showing that equivalent requirements were applied. Our analysis showed that Bulgarian Drug Agency inspectors rarely raised deficiencies related to Computer Systems, Qualification/Validation, Personnel and Qualification of Suppliers unlike other EU regulators agents.   Conclusions: Our analysis of Good Manufacturing Practice inspection findings in 2016 and 2017 showed that the Bulgarian Drug Agency demonstrated its ability to detect non-compliances and take necessary regulatory actions. Quality related issues constitute the main reasons for non-compliances with the requirements. Publishing the results from the inspections performed by the national competent authorities enhances the regulatory transparency that can be useful for industry to improve its Good Manufacturing Practice compliance.

The Effect of Formal and Informal Regulations on Industrial Effluents and Firm Compliance Behavior in Malaysia

“…It means that the non-compliant factories are more inclined to be penalized compared to the compliant factories. Similar finings are reported by (Joosen and Zhelyazkova, 2021;Stoimenova et al, 2020). The second hypothesis in this study was to test whether the Informal Regulation (IR) such as community pressure (CompP), competitor pressure (CP), investor pressure (IP), and market pressure (MP) would differ in the degree of influencing the industrial compliance and their relationship.…”

Pandemija COVID-19 mijenja uobičajen pristup u nadzoru nad dobrom proizvođačkom praksom

“…donijeti odluku o ukidanju proizvodne dozvole, ukidanju ili suspendiranju rješenja za stavljanje lijeka u promet, narediti povlačenje lijeka/djelatne tvari/ pomoćne tvari iz prometa ili obustavu njihova isporučivanja na teritoriju Republike Hrvatske, odnosno propisati druge regulatorne mjere). [19][20][21][22][23] Na temelju provedene inspekcije, izvješća i dostavljenog očitovanja o nedostatcima, inspektor izrađuje završni izvještaj i mišljenje o ispunjavanju uvjeta dobre proizvođačke prakse, temeljem kojeg se izdaje rješenje o davanju/ uskraćivanju/ izmjeni/ ukidanju proizvodne dozvole, rješenje o davanju ili uskraćivanju upisa/izmjene upisa u očevidnik ili rješenje o brisanju iz očevidnika proizvođača, uvoznika i veleprodaja djelatnih i/ili pomoćnih tvari, ili davanju potvrde o provođenju dobre proizvođačke prakse (GMP potvrda), odnosno u slučaju neispunjavanja uvjeta izdaje se Rješenje i Izjava o neispunjavanju uvjeta dobre proizvođačke prakse (engl. Non-Compliance).…”

Negative Opinion Of The EMA – Overview On Marketing Authorization Procedures Concluded With Rejection In 2018-2019

“…Производството на лекарства за хуманна употреба в Европейското икономическо пространство се ръководи от европейски правила и регламенти, съответстващи на принципите и насоките на Добрата производствена практика (1). Лекарствените продукти задължително трябва да отговарят на изискванията за качество, ефикасност и безопасност, за да бъдат допуснати и да започнат да се предлагат на фармацевтичния пазар.…”